Business Context and Reporting Period
Company: Advanced Biomed Inc. (ADVB)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Six months ended December 31, 2024
Business Overview: Advanced Biomed is a holding company incorporated in Nevada with primary operations in Taiwan and China. The company focuses on the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment. As of the reporting date, the company had no revenue-generating products and was in the pre-commercialization stage, awaiting regulatory approvals (NMPA) for its product candidates.
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 2024 | Six Months Ended Dec 31, 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,173,484) | $(916,661) |
| Operating Expenses | $(1,045,756) | $(1,091,547) |
| Cash and Cash Equivalents (End of Period) | $2,657,235 | $2,776,622 |
| Net Cash Used in Operating Activities | $(871,521) | $(584,854) |
| Total Assets | $4,504,152 | $4,460,247 |
| Total Liabilities | $3,885,120 | $2,796,989 |
| Working Capital (Deficit) | $(689,903) | $318,650 (Surplus) |
Note: The company reported no revenue for the period. Operating expenses consist primarily of Research and Development ($425,084) and General and Administrative ($620,672) costs.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately 28% (from $916,661 to $1,173,484) compared to the prior six-month period. This was primarily driven by a significant foreign exchange loss of approximately $113,419 in the current period, compared to a gain of $155,021 in the prior period.
- Working Capital Deterioration: The company moved from a working capital surplus of $318,650 as of June 30, 2024, to a deficit of $689,903 as of December 31, 2024. This shift was caused by a substantial increase in current liabilities, particularly amounts due to related parties and lease payables.
- Related Party Liabilities: Current liabilities increased significantly due to new unsecured, interest-free loans from major stockholders and related corporations to fund working capital. Amounts due to related parties rose from approximately $788,000 to $1.62 million.
- Asset Impairment: The company maintained a full impairment allowance of approximately $1.6 million on acquired patents, reflecting management's assessment that the carrying value is not recoverable.
Outlook, Risks, and Subsequent Events
- Going Concern Doubt: The filing explicitly states that the company's recurring losses, negative cash flows from operations, and working capital deficit raise substantial doubt about its ability to continue as a going concern. The company estimates its current cash reserves will sustain operations for approximately three months (until June 30, 2025) without additional financing.
- Financing Strategy: Management plans to raise capital through debt and equity financing, including support from related parties. Certain related parties have waived previous debts to improve working capital.
- Regulatory Timeline: The company plans to begin clinical research for its lung cancer screening kit (A+LCGuard) by the end of June 2025, with completion anticipated by April 2026. Regulatory approval is expected by October 2027. No revenue is expected until regulatory approvals are obtained.
- Subsequent Event (IPO): On March 7, 2025, the company completed its Initial Public Offering (IPO), issuing 1,640,000 shares at $4.00 per share for gross proceeds of $6.56 million. Shares began trading on the Nasdaq Capital Market under the ticker "ADVB" on March 6, 2025.
- Risks: Key risks include the inability to secure additional financing, delays in regulatory approvals, foreign currency fluctuations, and the failure of clinical trials to meet expectations.
Investor Verification Checklist
- Post-IPO Liquidity: Verify the net proceeds from the March 2025 IPO after deducting underwriting discounts and expenses to assess the updated runway for operations.
- Related Party Dependence: Review the terms of the unsecured, interest-free loans from major stockholders and related corporations to understand the company's reliance on insider funding.
- Regulatory Milestones: Monitor the progress of the A+LCGuard clinical trial registration and the NMPA review process for other product candidates.
- Asset Valuation: Confirm the status of the $1.6 million impairment on acquired patents and whether any new intangible assets have been capitalized.
- Share Structure: Note the retroactive adjustments for the 4-for-1 forward split (May 2023) and the 5-for-1 reverse split (October 2024) when analyzing historical share counts and per-share data.